Literature DB >> 3600816

Binding studies with [3H]cis-methyldioxolane in different tissues. Under certain conditions [3H]cis-methyldioxolane labels preferentially but not exclusively agonist high affinity states of muscarinic M2 receptors.

A Closse, H Bittiger, D Langenegger, A Wanner.   

Abstract

Special conditions--tricine buffer containing Ca2+ and Mg2+, 22 degrees C (TCM)--allow to label a much higher proportion of muscarinic receptors by [3H]cis-methyldioxolane (CD) than hitherto described (Vickroy et al. 1984a). Taking the maximum number of binding sites, Bmax, of [3H]QNB as 100%, Bmax of [3H]CD amounts to 83% in the rat heart instead of the reported 17%, 33% in the cerebral cortex instead of 6%, 20% in hippocampus and 55% in pons/medulla. In the salivary glands specific binding was negligible. The affinities of a number of muscarinic agonists and antagonists to [3H]CD and [3H]QNB binding sites in different tissues of the rat are compared. Apparent affinities of agonists are much higher in the [3H]CD system, affinities of antagonists are slightly higher in the [3H]QNB system. In both assay systems receptors of heart and pons/medulla membranes seem to have similar drug specificity. They differ somewhat from those in the cortex. Receptors in the salivary glands, however, seem to be completely different from those in the other three tissues. In the heart [3H]CD binding can be abolished almost completely by GppNHp. In the cortex about half of the [3H]CD binding is susceptible to GppNHp. The reduction of binding in the cortex is due to a change in Bmax and not in the dissociation constant KD. Competition of unlabelled pirenzepine with [3H]CD: In heart and pons/medulla only low affinity sites for pirenzepine (M2-receptors) are labelled by [3H]CD.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600816     DOI: 10.1007/bf00165550

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease.

Authors:  G J Wastek; H I Yamamura
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

2.  Affinity spectra: a novel way for the evaluation of equilibrium binding experiments.

Authors:  H J Tobler; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

3.  Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites.

Authors:  M Waelbroeck; P Robberecht; P Chatelain; J Christophe
Journal:  Mol Pharmacol       Date:  1982-05       Impact factor: 4.436

4.  The binding of antagonists to brain muscarinic receptors.

Authors:  E C Hulme; N J Birdsall; A S Burgen; P Mehta
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

5.  Muscarinic receptor binding in rat brain using the agonist, [3H]cis methyldioxolane.

Authors:  F J Ehlert; Y Dumont; W R Roeske; H I Yamamura
Journal:  Life Sci       Date:  1980-03-24       Impact factor: 5.037

6.  Regulation of muscarinic agonist binding by cations and guanine nucleotides.

Authors:  E C Hulme; C P Berrie; N J Birdsall; M Jameson; J M Stockton
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

7.  Muscarinic receptors in porcine caudate nucleus. I. Enhancement by nickel and other cations of [3H]cis-methyldioxolane binding to guanyl nucleotide-sensitive sites.

Authors:  T Nukada; T Haga; A Ichiyama
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

8.  Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies.

Authors:  R Cortés; J M Palacios
Journal:  Brain Res       Date:  1986-01-08       Impact factor: 3.252

9.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

10.  Binding of [3H]-pilocarpine to membranes from rat cerebral cortex.

Authors:  B Hedlund; T Bartfai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

View more
  2 in total

1.  SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; K McAllister; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release.

Authors:  P C Waldmeier; P Wicki; W Fröstl; H Bittiger; J J Feldtrauer; P A Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.